Guggenheim Sidelined on Mylan (MYL) Until More Clarity on M&A Strategy, FY18 Expectations is Offered

Go back to Guggenheim Sidelined on Mylan (MYL) Until More Clarity on M&A Strategy, FY18 Expectations is Offered

Mylan Third Quarter 2015 Constant Currency Adjusted Total Revenues Increase 36% and Adjusted Diluted EPS Increases 23% to $1.43

October 30, 2015 7:00 AM EDT

HERTFORDSHIRE, ENGLAND and PITTSBURGH, Oct. 30, 2015 /PRNewswire/ -- Mylan N.V. (Nasdaq: MYL) today announced its financial results for the quarter ended September 30, 2015.

Third Quarter 2015 Highlights

Adjusted total revenues of $2.71 billion, up 36% on a constant currency basis versus the prior year period. GAAP total revenues of $2.70 billion. Excluding the impact of the acquisition of Abbott's non-U.S. developed markets specialty and branded generics business ("EPD Business"), adjusted total revenues increased 14% on a constant currency basis, reflecting the continued strength in our legacy business. Foreign currency exchange rates... More

U.S. District Court Denies Perrigo's Motion for Preliminary Injunction Related to Certain Mylan Disclosures

October 30, 2015 6:45 AM EDT

HERTFORDSHIRE, England and PITTSBURGH, Oct. 30, 2015 /PRNewswire/ -- Mylan N.V. (Nasdaq: MYL) today announced that the U.S. District Court for the Southern District of New York has denied the motion by Perrigo Company plc (NYSE: PRGO; TASE) for a preliminary injunction concerning Mylan's proposed acquisition of Perrigo, ruling that Mylan had provided adequate public disclosures regarding the synergies expected to be achieved from the combination.

The court also ruled that Mylan's disclosures regarding its intention to de-list Perrigo from the NYSE and the TASE as soon as practicable following... More